Darbepoetin Alfa (Aranesp)

Covers darbepoetin alfa (Aranesp) for anemia due to chronic kidney disease in adults and pediatrics on or not on dialysis (non‑oncology uses only; oncology indications excluded). Approval (up to 12 months) requires documented CKD‑related anemia and dialysis status, required hemoglobin thresholds (initial non‑dialysis: adults Hb <10.0 g/dL, <18 yrs ≤11.0 g/dL; current ESA recipients: adults Hb <11.5 g/dL, <18 yrs ≤12.0 g/dL), evidence of adequate iron stores or current iron therapy for non‑dialysis patients, adherence to weight‑based dosing/route/frequency per policy, and supporting labs, weight, and prior ESA documentation.

"Treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis (FDA‑approved non-oncology indication)."

Sign up to see full coverage criteria, indications, and limitations.